Astellas Expands Manufacturing Footprint in America to Fuel Gene Therapy Innovation
Astellas’ investment in North Carolina will deliver life-changing therapies to patients with rare genetic conditions.
Astellas opened a state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina, advancing innovation for rare diseases with no or minimal treatment options and strengthening the world-leading U.S. biopharmaceutical manufacturing ecosystem.
The large-scale facility supports clinical- and commercial-scale manufacturing capabilities of adeno-associated virus (AAV) gene therapies, accelerating the development and delivery of life-changing treatments for patients with serious rare genetic conditions. Partnering with local community colleges, Astellas is creating more than 200 locally sourced high-skilled jobs, tapping into North Carolina’s robust life sciences workforce and reinforcing the region’s role as a leader in advanced manufacturing. Collaboration with local regulators and life science organizations demonstrates the valuable ecosystem of public and private partners in making new treatments possible.
With this expansion, Astellas is deepening its commitment to U.S. innovation, patients and the communities where it operates – building the future of gene therapy right here in America.
Our Work in Action
To maintain America’s global leadership, we need to support the next generation of innovation in medicine.
